KURA ONCOLOGY, INC. Deferred Tax Assets, in Process Research and Development
KURA ONCOLOGY, INC. (KURA) had Deferred Tax Assets, in Process Research and Development of $7.94 million as of 2020-12-31, per its 10-K filed 2021-02-24.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2021-02-24
- 2020-12-31: Deferred Tax Assets, in Process Research and Development $7.94M.
- 2019-12-31: Deferred Tax Assets, in Process Research and Development $4.75M.
- 2018-12-31: Deferred Tax Assets, in Process Research and Development $3.14M.
- 2017-12-31: Deferred Tax Assets, in Process Research and Development $1.69M.
| Period end | Deferred Tax Assets, in Process Research and Development |
|---|---|
| 2020-12-31 | $7.94M 10-K · filed 2021-02-24 |
| 2019-12-31 | $4.75M 10-K · filed 2021-02-24 |
| 2018-12-31 | $3.14M 10-K · filed 2020-02-25 |
| 2017-12-31 | $1.69M 10-K · filed 2019-03-05 |
| 2016-12-31 | $971.00K 10-K · filed 2018-03-12 |
| 2015-12-31 | $573.00K 10-K · filed 2017-03-14 |
| 2014-12-31 | $28.00K 10-K · filed 2016-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |